$RCEL
AVITA Medical, Inc.

2024 Q4 Form 10-Q Financial Statement

#000095017024123326 Filed on November 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $19.55M
YoY Change 43.25%
Cost Of Revenue $3.190M
YoY Change 50.97%
Gross Profit $16.36M
YoY Change 41.83%
Gross Profit Margin 83.68%
Selling, General & Admin $24.73M
YoY Change 48.5%
% of Gross Profit 151.22%
Research & Development $5.428M
YoY Change 23.53%
% of Gross Profit 33.19%
Depreciation & Amortization $288.0K
YoY Change 84.62%
% of Gross Profit 1.76%
Operating Expenses $30.16M
YoY Change 43.29%
Operating Profit -$13.81M
YoY Change 48.36%
Interest Expense $1.359M
YoY Change 13490.0%
% of Operating Profit
Other Income/Expense, Net -$1.068M
YoY Change -272.26%
Pretax Income -$16.23M
YoY Change 86.56%
Income Tax -$28.00K
% Of Pretax Income
Net Earnings -$16.21M
YoY Change 86.01%
Net Earnings / Revenue -82.91%
Basic Earnings Per Share -$0.62
Diluted Earnings Per Share -$0.62
COMMON SHARES
Basic Shares Outstanding 26.22M 25.99M
Diluted Shares Outstanding 25.98M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $44.41M
YoY Change -26.14%
Cash & Equivalents $18.64M
Short-Term Investments $25.77M
Other Short-Term Assets $2.892M
YoY Change 11023.08%
Inventory $6.229M
Prepaid Expenses
Receivables $10.29M
Other Receivables $111.0K
Total Short-Term Assets $63.93M
YoY Change -13.53%
LONG-TERM ASSETS
Property, Plant & Equipment $9.151M
YoY Change 391.46%
Goodwill
YoY Change
Intangibles $590.0K
YoY Change 28.54%
Long-Term Investments
YoY Change
Other Assets $546.0K
YoY Change 131.36%
Total Long-Term Assets $17.13M
YoY Change 141.65%
TOTAL ASSETS
Total Short-Term Assets $63.93M
Total Long-Term Assets $17.13M
Total Assets $81.05M
YoY Change 0.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.187M
YoY Change 39.57%
Accrued Expenses $9.776M
YoY Change 22.2%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $17.14M
YoY Change 44.82%
LONG-TERM LIABILITIES
Long-Term Debt $42.55M
YoY Change
Other Long-Term Liabilities $9.136M
YoY Change 47.35%
Total Long-Term Liabilities $42.55M
YoY Change 586.24%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.14M
Total Long-Term Liabilities $42.55M
Total Liabilities $68.60M
YoY Change 294.09%
SHAREHOLDERS EQUITY
Retained Earnings -$348.2M
YoY Change 19.7%
Common Stock $3.000K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $12.23M
YoY Change
Total Liabilities & Shareholders Equity $81.05M
YoY Change 0.05%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$16.21M
YoY Change 86.01%
Depreciation, Depletion And Amortization $288.0K
YoY Change 84.62%
Cash From Operating Activities -$7.214M
YoY Change -19.67%
INVESTING ACTIVITIES
Capital Expenditures $3.760M
YoY Change 637.25%
Acquisitions
YoY Change
Other Investing Activities $11.15M
YoY Change -49.91%
Cash From Investing Activities $7.394M
YoY Change -66.02%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.007M
YoY Change 67.83%
NET CHANGE
Cash From Operating Activities -7.214M
Cash From Investing Activities 7.394M
Cash From Financing Activities 1.007M
Net Change In Cash 1.187M
YoY Change -91.13%
FREE CASH FLOW
Cash From Operating Activities -$7.214M
Capital Expenditures $3.760M
Free Cash Flow -$10.97M
YoY Change 15.64%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001762303
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q3 us-gaap Investment Type Extensible Enumeration
InvestmentTypeExtensibleEnumeration
http://avitamedical.com/20240930#ContractualMaturitiesMember
CY2023Q4 us-gaap Investment Type Extensible Enumeration
InvestmentTypeExtensibleEnumeration
http://avitamedical.com/20240930#ContractualMaturitiesMember
CY2024Q3 us-gaap Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration
ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2024#GeneralAndAdministrativeExpense
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39059
dei Entity Registrant Name
EntityRegistrantName
AVITA MEDICAL, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1021707
dei Entity Address Address Line1
EntityAddressAddressLine1
28159 Avenue Stanford
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 220
dei Entity Address City Or Town
EntityAddressCityOrTown
Valencia
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
91355
dei City Area Code
CityAreaCode
(661)
dei Local Phone Number
LocalPhoneNumber
367-9170
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
RCEL
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
26217629
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18639000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22118000
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
25766000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
66939000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
10288000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7664000
CY2024Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
111000
CY2023Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
30000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2892000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1659000
CY2024Q3 us-gaap Fifo Inventory Amount
FIFOInventoryAmount
6229000
CY2023Q4 us-gaap Fifo Inventory Amount
FIFOInventoryAmount
5596000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
63925000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
104006000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9151000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1877000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3780000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2440000
CY2024Q3 rcel Corporate Owned Life Insurance Asset
CorporateOwnedLifeInsuranceAsset
3059000
CY2023Q4 rcel Corporate Owned Life Insurance Asset
CorporateOwnedLifeInsuranceAsset
2475000
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
590000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
487000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
546000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
355000
CY2024Q3 us-gaap Assets
Assets
81051000
CY2023Q4 us-gaap Assets
Assets
111640000
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4187000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3793000
CY2024Q3 rcel Accrued Wages And Fringe Benefits
AccruedWagesAndFringeBenefits
9776000
CY2023Q4 rcel Accrued Wages And Fringe Benefits
AccruedWagesAndFringeBenefits
7972000
CY2024Q3 rcel Non Qualified Deferred Compensation Plan Liability Current
NonQualifiedDeferredCompensationPlanLiabilityCurrent
1870000
CY2023Q4 rcel Non Qualified Deferred Compensation Plan Liability Current
NonQualifiedDeferredCompensationPlanLiabilityCurrent
168000
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1308000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1266000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
17141000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13199000
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
42547000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
39812000
CY2024Q3 rcel Non Qualified Deferred Compensation Plan Liability
NonQualifiedDeferredCompensationPlanLiability
2742000
CY2023Q4 rcel Non Qualified Deferred Compensation Plan Liability
NonQualifiedDeferredCompensationPlanLiability
3663000
CY2024Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
332000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
357000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3079000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1702000
CY2024Q3 rcel Warrant Liability
WarrantLiability
2759000
CY2023Q4 rcel Warrant Liability
WarrantLiability
3158000
CY2024Q3 us-gaap Liabilities
Liabilities
68600000
CY2023Q4 us-gaap Liabilities
Liabilities
61891000
CY2024Q3 rcel Non Qualified Deferred Compensation Plan Share Awards
NonQualifiedDeferredCompensationPlanShareAwards
224000
CY2023Q4 rcel Non Qualified Deferred Compensation Plan Share Awards
NonQualifiedDeferredCompensationPlanShareAwards
693000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26217629
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26217629
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25682078
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25682078
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
3000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 rcel Common Stock Held By Non Qualified Deferred Compensation Plan
CommonStockHeldByNonQualifiedDeferredCompensationPlan
-1255000
CY2023Q4 rcel Common Stock Held By Non Qualified Deferred Compensation Plan
CommonStockHeldByNonQualifiedDeferredCompensationPlan
-1130000
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
363769000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
350039000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2065000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1887000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-348225000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-297969000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
12227000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
49056000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
81051000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
111640000
CY2024Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
19394000
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
13645000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
45681000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
35948000
CY2024Q3 us-gaap Sales Type Lease Revenue
SalesTypeLeaseRevenue
152000
us-gaap Sales Type Lease Revenue
SalesTypeLeaseRevenue
164000
CY2024Q3 us-gaap Revenues
Revenues
19546000
CY2023Q3 us-gaap Revenues
Revenues
13645000
us-gaap Revenues
Revenues
45845000
us-gaap Revenues
Revenues
35948000
CY2024Q3 us-gaap Cost Of Revenue
CostOfRevenue
3190000
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
2113000
us-gaap Cost Of Revenue
CostOfRevenue
6814000
us-gaap Cost Of Revenue
CostOfRevenue
5984000
CY2024Q3 us-gaap Gross Profit
GrossProfit
16356000
CY2023Q3 us-gaap Gross Profit
GrossProfit
11532000
us-gaap Gross Profit
GrossProfit
39031000
us-gaap Gross Profit
GrossProfit
29964000
CY2023Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
212000
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
1369000
CY2024Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
15144000
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
10532000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
44086000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
27075000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9590000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6124000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26071000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20584000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5428000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4394000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15510000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14056000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
30162000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
21050000
us-gaap Operating Expenses
OperatingExpenses
85667000
us-gaap Operating Expenses
OperatingExpenses
61715000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13806000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9306000
us-gaap Operating Income Loss
OperatingIncomeLoss
-46636000
us-gaap Operating Income Loss
OperatingIncomeLoss
-30382000
CY2024Q3 us-gaap Interest Expense
InterestExpense
1359000
CY2023Q3 us-gaap Interest Expense
InterestExpense
10000
us-gaap Interest Expense
InterestExpense
4063000
us-gaap Interest Expense
InterestExpense
21000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1068000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
615000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
478000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2141000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16233000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8701000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-50221000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-28262000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-28000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
11000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
35000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
54000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-16205000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8712000
us-gaap Net Income Loss
NetIncomeLoss
-50256000
us-gaap Net Income Loss
NetIncomeLoss
-28316000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.62
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.62
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.95
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.95
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.12
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.12
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25983929
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25983929
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25401754
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25401754
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25794690
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25794690
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25281920
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25281920
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-16205000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8712000
us-gaap Net Income Loss
NetIncomeLoss
-50256000
us-gaap Net Income Loss
NetIncomeLoss
-28316000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-47000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-57000
CY2024Q3 rcel Gain Loss On Change In Fair Value Due To Credit Risk On Long Term Debt
GainLossOnChangeInFairValueDueToCreditRiskOnLongTermDebt
-554000
rcel Gain Loss On Change In Fair Value Due To Credit Risk On Long Term Debt
GainLossOnChangeInFairValueDueToCreditRiskOnLongTermDebt
-116000
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
45000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
65000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-62000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
407000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16714000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8694000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-50434000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-27966000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
23915000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-16205000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4040000
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1008000
CY2024Q3 rcel Distribution Diversification Of Common Stock Held By The Nqdc Plan
DistributionDiversificationOfCommonStockHeldByTheNqdcPlan
56000
CY2024Q3 rcel Change In Redemption Value Of Share Awards In Nqdc Plan
ChangeInRedemptionValueOfShareAwardsInNQDCPlan
-78
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
45000
CY2024Q3 rcel Change In Fair Value Due To Credit Risk On Long Term Debt
ChangeInFairValueDueToCreditRiskOnLongTermDebt
-554000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
12227000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
68647000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8712000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2367000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
110000
CY2023Q3 rcel Distribution Of Company Common Stock Held By The Nqdc Plan
DistributionOfCompanyCommonStockHeldByTheNQDCPlan
522000
CY2023Q3 rcel Change In Redemption Value Of Share Awards In Nqdc Plan
ChangeInRedemptionValueOfShareAwardsInNQDCPlan
26000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
65000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-47000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
62978000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
49056000
us-gaap Net Income Loss
NetIncomeLoss
-50256000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10603000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1701000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
786000
rcel Distribution Diversification Of Common Stock Held By The Nqdc Plan
DistributionDiversificationOfCommonStockHeldByTheNqdcPlan
321000
rcel Change In Redemption Value Of Share Awards In Nqdc Plan
ChangeInRedemptionValueOfShareAwardsInNQDCPlan
194000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-62000
rcel Change In Fair Value Due To Credit Risk On Long Term Debt
ChangeInFairValueDueToCreditRiskOnLongTermDebt
-116000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
12227000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
84740000
us-gaap Net Income Loss
NetIncomeLoss
-28316000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5738000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
942000
rcel Distribution Of Company Common Stock Held By The Nqdc Plan
DistributionOfCompanyCommonStockHeldByTheNQDCPlan
522000
rcel Change In Redemption Value Of Share Awards In Nqdc Plan
ChangeInRedemptionValueOfShareAwardsInNQDCPlan
-998000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-57000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
407000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
62978000
us-gaap Net Income Loss
NetIncomeLoss
-50256000
us-gaap Net Income Loss
NetIncomeLoss
-28316000
rcel Change In Fair Value Of Long Term Debt
ChangeInFairValueOfLongTermDebt
2619000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-399000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
717000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
445000
us-gaap Share Based Compensation
ShareBasedCompensation
10698000
us-gaap Share Based Compensation
ShareBasedCompensation
6213000
rcel Non Cash Lease Expense
NonCashLeaseExpense
633000
rcel Non Cash Lease Expense
NonCashLeaseExpense
531000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-25000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-83000
us-gaap Loss On Sale Of Investments
LossOnSaleOfInvestments
17000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-23000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
23000
rcel Excess And Obsolete Inventory Related Charges
ExcessAndObsoleteInventoryRelatedCharges
-408000
rcel Excess And Obsolete Inventory Related Charges
ExcessAndObsoleteInventoryRelatedCharges
-149000
rcel Estimated Deferred Costs
EstimatedDeferredCosts
-147000
us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
255000
us-gaap Provision For Loan Lease And Other Losses
ProvisionForLoanLeaseAndOtherLosses
33000
us-gaap Provision For Loan Lease And Other Losses
ProvisionForLoanLeaseAndOtherLosses
113000
rcel Amortization Of Premium Of Marketable Securities
AmortizationOfPremiumOfMarketableSecurities
-1479000
rcel Amortization Of Premium Of Marketable Securities
AmortizationOfPremiumOfMarketableSecurities
-794000
rcel Non Cash Changes In Fair Value Of Non Qualified Deferred Compensation Plan
NonCashChangesInFairValueOfNonQualifiedDeferredCompensationPlan
-36000
rcel Non Cash Changes In Fair Value Of Non Qualified Deferred Compensation Plan
NonCashChangesInFairValueOfNonQualifiedDeferredCompensationPlan
-899000
rcel Increase Decrease In Trade And Other Receivables
IncreaseDecreaseInTradeAndOtherReceivables
-2656000
rcel Increase Decrease In Trade And Other Receivables
IncreaseDecreaseInTradeAndOtherReceivables
-2473000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
81000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-697000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1233000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2057000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1041000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2405000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-667000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-571000
rcel Increase Decrease In Corporate Owned Life Insurance Asset
IncreaseDecreaseInCorporateOwnedLifeInsuranceAsset
271000
rcel Increase Decrease In Corporate Owned Life Insurance Asset
IncreaseDecreaseInCorporateOwnedLifeInsuranceAsset
643000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
192000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
114000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-65000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-70000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
1804000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
524000
rcel Increase Decrease In Current Non Qualified Deferred Compensation Liability
IncreaseDecreaseInCurrentNonQualifiedDeferredCompensationLiability
1625000
rcel Increase Decrease In Current Non Qualified Deferred Compensation Liability
IncreaseDecreaseInCurrentNonQualifiedDeferredCompensationLiability
-651000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
112000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
345000
us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
-1242000
us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
1174000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-25000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-333000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-40858000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27148000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
18609000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
7633000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
2372000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
61200000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
65289000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7559000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1085000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
140000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
32000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
34892000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
58911000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1701000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
942000
rcel Employee Stock Purchase Plan Espp Purchases
EmployeeStockPurchasePlanEsppPurchases
786000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2487000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
942000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-15000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3479000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
32690000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22118000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18164000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18639000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
50854000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
21000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
44000
us-gaap Interest Paid Net
InterestPaidNet
4062000
us-gaap Interest Paid Net
InterestPaidNet
21000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
407000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
114000
rcel Right Of Use Asset Obtained In Exchange For Lease Liabilities
RightOfUseAssetObtainedInExchangeForLeaseLiabilities
2026000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the accompanying Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts (including the stand-alone selling price (“SSP”</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) for the RPD, allowance for credit losses, reserves for inventory excess and obsolescence, carrying value of long-lived assets, the useful lives of long-lived assets, accounting for marketable securities, income taxes, fair value of debt, fair value of warrants and stock-based compensation) and related disclosures. Estimates have been prepared based on the current and available information. However, actual results could differ from estimated amounts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2024Q3 us-gaap Foreign Currency Transaction Gain Loss After Tax
ForeignCurrencyTransactionGainLossAfterTax
-11000
us-gaap Foreign Currency Transaction Gain Loss After Tax
ForeignCurrencyTransactionGainLossAfterTax
-23000
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss After Tax
ForeignCurrencyTransactionGainLossAfterTax
26000
us-gaap Foreign Currency Transaction Gain Loss After Tax
ForeignCurrencyTransactionGainLossAfterTax
23000
CY2024Q3 rcel Cash At Deposit Institutions
CashAtDepositInstitutions
5300000
CY2023Q4 rcel Cash At Deposit Institutions
CashAtDepositInstitutions
10700000
CY2024Q3 rcel Cash In Foreign Institutions
CashInForeignInstitutions
0
CY2023Q4 rcel Cash In Foreign Institutions
CashInForeignInstitutions
69000
CY2024Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
13300000
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
11400000
us-gaap Deferred Compensation Arrangement With Individual Shares Issued
DeferredCompensationArrangementWithIndividualSharesIssued
91026
CY2023 us-gaap Deferred Compensation Arrangement With Individual Shares Issued
DeferredCompensationArrangementWithIndividualSharesIssued
81052
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, trade receivables, and debt and other liabilities. As of September 30, 2024 and December 31, 2023, substantially all the Company’s cash and cash equivalents were deposited in accounts at financial institutions, and those deposited amounts exceed federally insured limits and are subject to the risk of bank failure.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of September 30, 2024 and December 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">no</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> single commercial customer accounted for more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of net accounts receivable or more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of revenues for the three-months and nine-months ended September 30, 2024 and 2023.</span></p>
CY2024Q3 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
25732000
CY2024Q3 rcel Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
34000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
25766000
CY2023Q4 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
66844000
CY2023Q4 rcel Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
100000
CY2023Q4 rcel Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
5000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
66939000
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
25732000
CY2024Q3 rcel Available For Sale Securities Debt Maturities Within One Year Carrying Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearCarryingValue
25766000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
66844000
CY2023Q4 rcel Available For Sale Securities Debt Maturities Within One Year Carrying Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearCarryingValue
66939000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
34000
CY2023 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
95000
CY2024Q3 us-gaap Proceeds From Sale Of Other Investments
ProceedsFromSaleOfOtherInvestments
0
us-gaap Proceeds From Sale Of Other Investments
ProceedsFromSaleOfOtherInvestments
0
CY2023Q3 us-gaap Proceeds From Sale Of Other Investments
ProceedsFromSaleOfOtherInvestments
0
us-gaap Proceeds From Sale Of Other Investments
ProceedsFromSaleOfOtherInvestments
0
CY2024Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2023Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2024Q3 us-gaap Sales Type Lease Revenue
SalesTypeLeaseRevenue
152000
us-gaap Sales Type Lease Revenue
SalesTypeLeaseRevenue
164000
CY2024Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
365000
CY2023Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
390000
CY2024Q3 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2023Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2024Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
40000000
CY2024Q3 rcel Debt Instrument Outstanding Amount Addition Reduction To Liability
DebtInstrumentOutstandingAmountAdditionReductionToLiability
2500000
CY2023Q4 rcel Debt Instrument Outstanding Amount Addition Reduction To Liability
DebtInstrumentOutstandingAmountAdditionReductionToLiability
-188000
CY2024Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2731000
CY2023Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
3683000
CY2024Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
427000
CY2023Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
878000
CY2024Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
3071000
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1035000
CY2024Q3 us-gaap Inventory Net
InventoryNet
6229000
CY2023Q4 us-gaap Inventory Net
InventoryNet
5596000
CY2024Q3 rcel Excess And Obsolete Inventory Related Charges
ExcessAndObsoleteInventoryRelatedCharges
-173000
CY2023Q3 rcel Excess And Obsolete Inventory Related Charges
ExcessAndObsoleteInventoryRelatedCharges
-81000
rcel Excess And Obsolete Inventory Related Charges
ExcessAndObsoleteInventoryRelatedCharges
-408000
rcel Excess And Obsolete Inventory Related Charges
ExcessAndObsoleteInventoryRelatedCharges
-149000
CY2024Q3 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
753000
CY2024Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
163000
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
590000
CY2023Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
616000
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
129000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
487000
CY2024Q3 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
CY2023Q3 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
CY2024Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
23000
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
9000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
56000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
26000
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
47000
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
93000
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
49000
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
40000
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
40000
CY2024Q3 rcel Finite Lived Intangible Assets Amortization Expense After Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
267000
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
536000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3051000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2432000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9151000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1877000
rcel Recell Go Processing Device Maximum Number Of Uses
RecellGoProcessingDeviceMaximumNumberOfUses
200
CY2024Q3 us-gaap Depreciation
Depreciation
288000
CY2023Q3 us-gaap Depreciation
Depreciation
156000
us-gaap Depreciation
Depreciation
661000
us-gaap Depreciation
Depreciation
419000
CY2024Q3 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2024Q3 us-gaap Operating Lease Variable Lease Income
OperatingLeaseVariableLeaseIncome
152000
us-gaap Operating Lease Variable Lease Income
OperatingLeaseVariableLeaseIncome
164000
CY2024Q3 us-gaap Property Subject To Or Available For Operating Lease Gross
PropertySubjectToOrAvailableForOperatingLeaseGross
1071000
CY2024Q3 us-gaap Property Subject To Or Available For Operating Lease Accumulated Depreciation
PropertySubjectToOrAvailableForOperatingLeaseAccumulatedDepreciation
24000
CY2024Q3 us-gaap Property Subject To Or Available For Operating Lease Net
PropertySubjectToOrAvailableForOperatingLeaseNet
1047000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2024Q3 us-gaap Revenues
Revenues
19546000
CY2023Q3 us-gaap Revenues
Revenues
13645000
us-gaap Revenues
Revenues
45845000
us-gaap Revenues
Revenues
35948000
CY2024Q3 us-gaap Revenues
Revenues
19546000
CY2023Q3 us-gaap Revenues
Revenues
13645000
us-gaap Revenues
Revenues
45845000
us-gaap Revenues
Revenues
35948000
CY2024Q3 us-gaap Cost Of Revenue
CostOfRevenue
3190000
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
2113000
us-gaap Cost Of Revenue
CostOfRevenue
6814000
us-gaap Cost Of Revenue
CostOfRevenue
5984000
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26217629
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26217629
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25682078
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25682078
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
0
CY2023Q3 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
0
us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
0
us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
0
CY2023Q2 rcel Employee Stock Purchases Plan Effective Date
EmployeeStockPurchasesPlanEffectiveDate
2023-07-01
CY2023Q2 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
1000000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4080000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2430000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10698000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6213000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2690158
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1942658
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
301524
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
300902
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
239369
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3791021
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
1309872
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3791021
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
235132
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
55200
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
137774
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
24104
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
128454
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-28000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
11000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
35000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
54000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-16205000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8712000
us-gaap Net Income Loss
NetIncomeLoss
-50256000
us-gaap Net Income Loss
NetIncomeLoss
-28316000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25984000
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25984000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25402000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25402000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25795000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25795000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25282000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25282000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.62
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.62
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.95
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.95
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.12
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.12
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
122294
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-123326-index-headers.html Edgar Link pending
0000950170-24-123326-index.html Edgar Link pending
0000950170-24-123326.txt Edgar Link pending
0000950170-24-123326-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img179650235_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
rcel-20240930.htm Edgar Link pending
rcel-20240930.xsd Edgar Link pending
rcel-ex10_1.htm Edgar Link pending
rcel-ex10_2.htm Edgar Link pending
rcel-ex10_3.htm Edgar Link pending
rcel-ex10_4.htm Edgar Link pending
rcel-ex31_1.htm Edgar Link pending
rcel-ex31_2.htm Edgar Link pending
rcel-ex32.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
rcel-20240930_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable